Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells

Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin lymphoma (NHL) producing higher overall response and complete remission rates compared with unlabelled antibodies. However, the majority of patients treated with conventional or myeloablative doses of radiolabelled antibodies r...

Descripción completa

Detalles Bibliográficos
Autores principales: Roscher, Mareike, Hormann, Inis, Leib, Oliver, Marx, Sebastian, Moreno, Josue, Miltner, Erich, Friesen, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712568/
https://www.ncbi.nlm.nih.gov/pubmed/23474846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712568/
https://www.ncbi.nlm.nih.gov/pubmed/23474846

Ejemplares similares